Skip to main content

Alentis raises 105 million US dollars

| News

Alentis raises 105 million US dollars


Alentis Therapeutics has received 105 million US dollars in a series C funding round. It will invest the funds in the phase I and II programs for two antibodies targeting Claudin-1. This is a protein that plays an important part in organ fibrosis and certain types of cancer. With this financing round companies supported by the incubator BaseLaunch have received 550 million US dollars from investors since the start in 2018.

Alentis Therapeutics, a biotech company based in Basel, has announced that it has concluded a series C funding round amounting to 105 million US dollars. The startup funding round was led by Jeito Capital together with Novo Holdings and RA Capital Management. Existing investors were also involved.

Alentis is a clinical-stage biotechnology company that develops potentially pioneering therapies for organ fibrosis and CLDN1-positive tumors. CLDN1 is a gene that codes the protein Claudin-1. This hitherto unexplored target molecule plays a vital role in the pathology of tumors with immune-evasive properties and fibrotic diseases in multiple organs. With its bispecific antibodies and CLDN1 antibody active substance conjugates, Alentis is a CLDN1 pioneer targeting an innovative approach to modify and reverse the disease course.

Roberto Iacone, CEO at Alentis Therapeutics, commented: “There are huge unmet needs in organ fibrosis and cancer, and this funding enables us to continue with the important work we’re doing in the CLDN1 space and generate clinical data from both our programs.”

Incubator BaseLaunch supported Alentis

The founder and CEO of anchor investor Jeito Capital, Rafaèle Tordjman, is “totally convinced” of the potential of the CLDN1 biology in various areas of fibrosis and oncology. She adds that Alentis is “the leading player in the CLDN1 space.”

The Basel-based company concluded a series A funding round with 12.5 million Swiss francs in 2019. This was followed by a series B round in 2021, which raised an additional 67 million US dollars.

Alentis was supported by the incubator BaseLaunch in the early startup stages. This funding round brings the total received by BaseLaunch’s portfolio companies from investors to 550 million US dollars since the start of 2018. These figures put BaseLaunch among the absolute top biotech incubators in Europe. BaseLaunch as well as Alentis are based in the Main Campus of the Switzerland Innovation Park Basel Area.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Do you have a question? We'd like to hear from you.